Chugai Of Japan Ties With U.S. Firm To Develop Key Hepatitis Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical has signed an agreement with Romark Laboratories of the United States to develop a nitazoxanide drug to treat hepatitis C. The drug is in the relatively new class of thiazolide antiviral drugs invented by the chairman of Romark. The firm, already is developing thiazolides for other treatments, including hepatitis B. Few details of the tie-up were detailed beyond payment schedules. (Click here for more